# PLD2

## Overview
Phospholipase D2 (PLD2) is a gene that encodes the enzyme phospholipase D2, a member of the phospholipase D family, which plays a pivotal role in cellular signaling pathways. The enzyme is primarily involved in the hydrolysis of phosphatidylcholine to generate phosphatidic acid, a key lipid second messenger involved in various cellular processes such as cell proliferation, migration, and cytoskeletal organization (GomezCambronero2014Phospholipase; Bowling2021Structure). Phospholipase D2 is characterized by its structural domains, including PX and PH domains, which facilitate its membrane association and guanine nucleotide exchange factor (GEF) activity, particularly in the activation of small GTPases like Rac2 (Mahankali2011Phospholipase; GomezCambronero2012Biochemical). The enzyme's activity is regulated by post-translational modifications, such as phosphorylation, which are mediated by protein tyrosine kinases (GomezCambronero2012Biochemical). PLD2 is implicated in various pathological conditions, including cancer, Alzheimer's disease, and cardiovascular disorders, highlighting its significance as a potential therapeutic target (MuñozGalván2024Essential; McDermott2020Mammalian; Nelson2017Phospholipase).

## Structure
Phospholipase D2 (PLD2) is a protein characterized by several distinct structural features that contribute to its function. The primary structure of PLD2 includes 933 amino acids, and it is a 106-kDa protein (Cockcroft2001Signalling). The protein contains two conserved HKD motifs, which are essential for its catalytic activity, facilitating the hydrolysis of phosphatidylcholine to produce phosphatidic acid and choline (Yao2021Structural; GomezCambronero2012Biochemical).

PLD2 also possesses a PX (phox homology) domain and a PH (pleckstrin homology) domain at its N-terminus. These domains are involved in membrane association and are crucial for the protein's guanine nucleotide exchange factor (GEF) activity, particularly in the activation of the small GTPase Rac2 (Mahankali2011Phospholipase; GomezCambronero2012Biochemical). The PX domain is rich in α-helical structures, while the PH domain forms a barrel-like structure, both contributing to the protein's interaction with phosphoinositides (Yao2021Structural).

Post-translational modifications, such as phosphorylation at specific tyrosine residues (Y296, Y415, and Y511), regulate PLD2's activity. These modifications are mediated by protein tyrosine kinases like EGFR, JAK3, and Src (GomezCambronero2012Biochemical). PLD2 does not have a DH domain, which is typical in classical RhoGEFs, making its GEF activity unique (Mahankali2011Phospholipase).

## Function
Phospholipase D2 (PLD2) is a crucial enzyme involved in various cellular processes in healthy human cells. It primarily functions by hydrolyzing phosphatidylcholine to produce phosphatidic acid (PA), a lipid second messenger that plays a significant role in cell signaling pathways, including those regulating cell proliferation, migration, and cytoskeletal organization (GomezCambronero2014Phospholipase; Bowling2021Structure).

PLD2 is predominantly localized to the plasma membrane, where it is constitutively active, and it translocates to internal cellular membranes upon signaling events (Bowling2021Structure; Colley1997Phospholipase). Its activity is essential for receptor-mediated endocytosis, particularly in the internalization of receptors such as the epidermal growth factor receptor (EGFR), where it interacts with dynamin to stimulate its GTPase activity (Hongu2014Mammalian).

In addition to its lipase activity, PLD2 also exhibits guanine nucleotide exchange factor (GEF) activity, which is significant for the activation of small GTPases like Rac2, influencing actin cytoskeleton reorganization and cell migration (GomezCambronero2014Phospholipase; GomezCambronero2012Biochemical). This dual function allows PLD2 to act as a scaffold protein, enhancing signaling efficiency and compartmentalization at sites such as the phagocytic cup or the leading edge of a migrating cell (GomezCambronero2012Biochemical).

## Clinical Significance
Phospholipase D2 (PLD2) is implicated in various diseases due to its altered expression or activity. In ovarian cancer, PLD2 overexpression is linked to chemotherapy resistance, particularly in high-grade serous ovarian cancer. This resistance is associated with an increase in cancer stem cell-like cells, which contribute to tumor relapse. Targeting PLD2 with inhibitors has shown potential in reducing tumor growth and increasing survival in preclinical models (MuñozGalván2024Essential).

In neurological conditions, PLD2 is associated with Alzheimer's disease, where its activity is increased, contributing to amyloid β accumulation and neurotoxicity. PLD2 deletion in transgenic mouse models of Alzheimer's has been shown to block synaptotoxicity and improve cognitive deficits, suggesting a protective role against the disease (McDermott2020Mammalian; Oliveira2010Phospholipase).

PLD2 also plays a role in cardiovascular health. Its loss leads to increased blood pressure due to decreased endothelial nitric oxide synthase (eNOS) activity, which is crucial for vasodilation. This mechanism highlights a potential link between PLD2 mutations and hypertension (Nelson2017Phospholipase).

In cancer, PLD2 is involved in processes like epithelial-to-mesenchymal transition, extracellular matrix degradation, and cell motility, which are critical for cancer invasion and metastasis (Yao2020Phospholipase).

## Interactions
Phospholipase D2 (PLD2) is involved in various protein interactions that play significant roles in cellular signaling pathways. PLD2 interacts with the growth factor receptor-bound protein 2 (Grb2) through specific tyrosine residues, Y169 and Y179. These interactions are crucial for the recruitment of Sos, a guanine nucleotide exchange factor, which activates the Ras/MAPK signaling pathway, leading to cellular proliferation (Di2006The). The binding of Grb2 to PLD2 is mediated by the SH2 domain of Grb2, and mutations at these tyrosine residues can significantly reduce Grb2 binding (Di2006The).

PLD2 also interacts with small GTPases, such as Rac2, through its PX and PH domains, facilitating GDP/GTP exchange and acting as a guanine nucleotide exchange factor (GEF) (GomezCambronero2012Biochemical). This interaction is significant for processes like cell migration and phagocytosis in leukocytes (GomezCambronero2012Biochemical).

Additionally, PLD2 is regulated by phosphorylation through protein tyrosine kinases such as EGFR, Src, and JAK3, which target specific phosphorylation sites on PLD2, affecting its lipase activity (GomezCambronero2012Biochemical). These interactions and modifications highlight the complex regulatory network involving PLD2 in cellular processes.


## References


[1. (Mahankali2011Phospholipase) Madhu Mahankali, Hong-Juan Peng, Karen M. Henkels, Mary C. Dinauer, and Julian Gomez-Cambronero. Phospholipase d2 (pld2) is a guanine nucleotide exchange factor (gef) for the gtpase rac2. Proceedings of the National Academy of Sciences, 108(49):19617–19622, November 2011. URL: http://dx.doi.org/10.1073/pnas.1114692108, doi:10.1073/pnas.1114692108. This article has 53 citations.](https://doi.org/10.1073/pnas.1114692108)

[2. (GomezCambronero2014Phospholipase) Julian Gomez-Cambronero. Phospholipase d in cell signaling: from a myriad of cell functions to cancer growth and metastasis. Journal of Biological Chemistry, 289(33):22558–22566, August 2014. URL: http://dx.doi.org/10.1074/jbc.R114.574152, doi:10.1074/jbc.r114.574152. This article has 89 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.R114.574152)

[3. (Bowling2021Structure) Forrest Z. Bowling, Michael A. Frohman, and Michael V. Airola. Structure and regulation of human phospholipase d. Advances in Biological Regulation, 79:100783, January 2021. URL: http://dx.doi.org/10.1016/j.jbior.2020.100783, doi:10.1016/j.jbior.2020.100783. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jbior.2020.100783)

[4. (Hongu2014Mammalian) Tsunaki Hongu and Yasunori Kanaho. Mammalian Phospholipase D: Structure, Regulation, and Physiological Function of Phospholipase D and its Link to Pathology, pages 343–358. Springer New York, 2014. URL: http://dx.doi.org/10.1007/978-1-4939-0464-8_21, doi:10.1007/978-1-4939-0464-8_21. This article has 0 citations.](https://doi.org/10.1007/978-1-4939-0464-8_21)

[5. (GomezCambronero2012Biochemical) Julian Gomez-Cambronero. Biochemical and cellular implications of a dual lipase-gef function of phospholipase d2 (pld2). Journal of Leukocyte Biology, 92(3):461–467, July 2012. URL: http://dx.doi.org/10.1189/jlb.0212073, doi:10.1189/jlb.0212073. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1189/jlb.0212073)

[6. (Oliveira2010Phospholipase) Tiago Gil Oliveira, Robin B. Chan, Huasong Tian, Mikael Laredo, Guanghou Shui, Agnieszka Staniszewski, Hong Zhang, Lili Wang, Tae-Wan Kim, Karen E. Duff, Markus R. Wenk, Ottavio Arancio, and Gilbert Di Paolo. Phospholipase d2 ablation ameliorates alzheimer’s disease-linked synaptic dysfunction and cognitive deficits. The Journal of Neuroscience, 30(49):16419–16428, December 2010. URL: http://dx.doi.org/10.1523/jneurosci.3317-10.2010, doi:10.1523/jneurosci.3317-10.2010. This article has 146 citations.](https://doi.org/10.1523/jneurosci.3317-10.2010)

[7. (Cockcroft2001Signalling) S. Cockcroft. Signalling roles of mammalian phospholipase d1 and d2. Cellular and Molecular Life Sciences CMLS, 58(11):1674–1687, October 2001. URL: http://dx.doi.org/10.1007/PL00000805, doi:10.1007/pl00000805. This article has 241 citations.](https://doi.org/10.1007/PL00000805)

[8. (Yao2021Structural) Yuanfa Yao, Jianxu Li, Yinyan Lin, Jiaqiang Zhou, Peng Zhang, and Yingke Xu. Structural insights into phospholipase d function. Progress in Lipid Research, 81:101070, January 2021. URL: http://dx.doi.org/10.1016/j.plipres.2020.101070, doi:10.1016/j.plipres.2020.101070. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.plipres.2020.101070)

[9. (Nelson2017Phospholipase) Rochelle K. Nelson, Jiang Ya-Ping, John Gadbery, Danya Abedeen, Nicole Sampson, Richard Z. Lin, and Michael A. Frohman. Phospholipase d2 loss results in increased blood pressure via inhibition of the endothelial nitric oxide synthase pathway. Scientific Reports, August 2017. URL: http://dx.doi.org/10.1038/s41598-017-09852-4, doi:10.1038/s41598-017-09852-4. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-017-09852-4)

[10. (Colley1997Phospholipase) William C. Colley, Tsung-Chang Sung, Richard Roll, John Jenco, Scott M. Hammond, Yelena Altshuller, Dafna Bar-Sagi, Andrew J. Morris, and Michael A. Frohman. Phospholipase d2, a distinct phospholipase d isoform with novel regulatory properties that provokes cytoskeletal reorganization. Current Biology, 7(3):191–201, March 1997. URL: http://dx.doi.org/10.1016/s0960-9822(97)70090-3, doi:10.1016/s0960-9822(97)70090-3. This article has 562 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0960-9822(97)70090-3)

[11. (MuñozGalván2024Essential) Sandra Muñoz-Galván, Eva M. Verdugo-Sivianes, José M. Santos-Pereira, Purificación Estevez-García, and Amancio Carnero. Essential role of pld2 in hypoxia-induced stemness and therapy resistance in ovarian tumors. Journal of Experimental &amp; Clinical Cancer Research, February 2024. URL: http://dx.doi.org/10.1186/s13046-024-02988-y, doi:10.1186/s13046-024-02988-y. This article has 1 citations.](https://doi.org/10.1186/s13046-024-02988-y)

[12. (McDermott2020Mammalian) M.I. McDermott, Y. Wang, M.J.O. Wakelam, and V.A. Bankaitis. Mammalian phospholipase d: function, and therapeutics. Progress in Lipid Research, 78:101018, April 2020. URL: http://dx.doi.org/10.1016/j.plipres.2019.101018, doi:10.1016/j.plipres.2019.101018. This article has 57 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.plipres.2019.101018)

[13. (Di2006The) M Di Fulvio, N Lehman, X Lin, I Lopez, and J Gomez-Cambronero. The elucidation of novel sh2 binding sites on pld2. Oncogene, 25(21):3032–3040, January 2006. URL: http://dx.doi.org/10.1038/sj.onc.1209340, doi:10.1038/sj.onc.1209340. This article has 37 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1209340)

[14. (Yao2020Phospholipase) Yuanfa Yao, Xinyi Wang, Hanbing Li, Jiannan Fan, Xiaohan Qian, Hong Li, and Yingke Xu. Phospholipase d as a key modulator of cancer progression. Biological Reviews, 95(4):911–935, February 2020. URL: http://dx.doi.org/10.1111/brv.12592, doi:10.1111/brv.12592. This article has 36 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/brv.12592)